Related scientific articles (all)

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.

Authors : Guiu S, Michiels S, André F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, van de Vijver M, Viale G, Loi S, Reis-Filho JS
Year : 2012
Journal : Ann Oncol
Volume : 23(12)
Pages : 2997-3006

Treatment Options in Anthracycline and/or Taxane Pretreated Patients with Metastatic Breast Cancer.

Authors : Pugliano L, de Azambuja E
Year : 2012
Journal : Onkologie
Volume : 35(9)
Pages : 476-8

Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC).

Authors : Klastersky J, Awada A
Year : 2012
Journal : Crit Rev Oncol Hematol
Volume : 81(1)
Pages : 49-57

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence.

Authors : Rossari JR, Metzger-Filho O, Paesmans M, Saini KS, Gennari A, de Azambuja E, Piccart-Gebhart M
Year : 2012
Journal : J Oncol
Volume : 2012
Pages : 417673

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.

Authors : Guiu S, Michiels S, André F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, van de Vijver M, Viale G, Loi S, Reis-Filho JS
Year : 2012
Journal : Ann Oncol
Volume : 23
Pages : 2997-3006

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Authors : Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber Rd, Piccart-Gebhart M
Year : 2012
Journal : Lancet
Volume : 379(9816)
Pages : 633-40

New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel.

Authors : Van Laethem JL, Verslype C, Iovanna JL, Michl P, Conroy T, Louvet C, Hammel P, Mitry E, Ducreux M, Maraculla T, Uhl W, Van Tienhoven G, Bachet JB, Maréchal R, Hendlisz A, Bali M, Demetter P, Ulrich F, Aust D, Luttges J, Peeters M, Mauer M, Roth A, Neoptolemos JP, Lutz M
Year : 2012
Journal : Ann Oncol
Volume : 23
Pages : 570-576

Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01).

Authors : Azim HA, Metzger-Filho O, de Azambuja E, Loibl S, Focant F, Gresko E, Arfi M, Piccart-Gebhart M
Year : 2012
Journal : Breast Cancer Res. Treat.
Volume : 133(1)
Pages : 387-91

Dissecting the heterogeneity of triple-negative breast cancer.

Authors : Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M
Year : 2012
Journal : J. Clin. Oncol.
Volume : 30(15)
Pages : 1879-87

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.

Authors : Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F
Year : 2012
Journal : Ann Oncol
Volume : 23 Suppl 7
Pages : vii155-66

Targeted therapies in breast cancer: are heart and vessels also being targeted?

Authors : Criscitiello C, Metzger-Filho O, Saini KS, de Castro G, Diaz M, La Gerche A, de Azambuja E, Piccart-Gebhart M
Year : 2012
Journal : Breast Cancer Res
Volume : 14(3)
Pages : 209

Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.

Authors : Pradeep CR, Zeisel A, Köstler WJ, Lauriola M, Jacob-Hirsch J, Haibe-Kains B, Amariglio N, Ben-Chetrit N, Emde A, Solomonov I, Neufeld G, Piccart-Gebhart M, Sagi I, Sotiriou C, Rechavi G, Domany E, Desmedt C, Yarden Y
Year : 2012
Journal : Oncogene
Volume : 31(31)
Pages : 3569-83

Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer.

Authors : Zardavas D, Bozovic-Spasojevic I, de Azambuja E
Year : 2012
Journal : Curr Opin Oncol
Volume : 24(6)
Pages : 612-22

Technological innovation and healthcare professionals' workloads: an ambiguous relationship.

Authors : de Pires DE, Bertoncini JH, Trindade Lde L, Matos E, de Azambuja E, Borges AM
Year : 2012
Journal : Rev Gaucha Enferm
Volume : 33(1)
Pages : 157-68

Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.

Authors : Awada A, Hendlisz A, Christensen O, Lathia CD, Bartholomeus S, Lebrun F, de Valeriola D, Brendel E, Radtke M, Delaunoit T, Piccart-Gebhart M, Gil T
Year : 2012
Journal : Eur. J. Cancer
Volume : 48(4)
Pages : 465-74

Clinical development of insulin-like growth factor receptor-1 (IGF-1R) inhibitors: At the crossroad?

Authors : Gombos A, Metzger-Filho O, Dal Lago L, Awada A
Year : 2012
Journal : Invest New Drugs
Volume : 30(6)
Pages : 2433-42

Second primary cancers in head and neck cancer patients: a challenging entity.

Authors : de Castro G, Awada A
Year : 2012
Journal : Curr Opin Oncol
Volume : 24(3)
Pages : 203-4

Thérapies biologiques ciblées et cancer thyroïdien récidivant : enfin un standard thérapeutique ?

Authors : Lalami Y
Year : 2012
Journal : Onco-Hémato
Volume : 6(5)
Pages : 45-51

Triple-negative breast cancer in focus: from biology to novel therapeutics. Editorial.

Authors : Piccart-Gebhart M
Year : 2012
Journal : Ann Oncol
Volume : 23 Suppl 6
Pages : vi5-vi6

Clinical development of new formulations of cytotoxics in solid tumors.

Authors : Azim HA, Awada A
Year : 2012
Journal : Curr Opin Oncol
Volume : 24(3)
Pages : 325-31